NDC 72934-1052

CLINDAMYCIN 1% / NIACINAMIDE 4% / SPIRONOLACTONE 2% / TRETINOIN 0.025%

Clindamycin 1% / Niacinamide 4% / Spironolactone 2% / Tretinoin 0.025%

CLINDAMYCIN 1% / NIACINAMIDE 4% / SPIRONOLACTONE 2% / TRETINOIN 0.025% is a Topical Gel in the Human Prescription Drug category. It is labeled and distributed by Sincerus Florida, Llc. The primary component is Spironolactone; Tretinoin; Clindamycin Phosphate; Niacinamide.

Product ID72934-1052_88005838-bdcc-1203-e053-2a95a90a9c29
NDC72934-1052
Product TypeHuman Prescription Drug
Proprietary NameCLINDAMYCIN 1% / NIACINAMIDE 4% / SPIRONOLACTONE 2% / TRETINOIN 0.025%
Generic NameClindamycin 1% / Niacinamide 4% / Spironolactone 2% / Tretinoin 0.025%
Dosage FormGel
Route of AdministrationTOPICAL
Marketing Start Date2019-05-04
Marketing CategoryUNAPPROVED DRUG OTHER / UNAPPROVED DRUG OTHER
Labeler NameSincerus Florida, LLC
Substance NameSPIRONOLACTONE; TRETINOIN; CLINDAMYCIN PHOSPHATE; NIACINAMIDE
Active Ingredient Strength2 g/100g; g/100g; g/100g; g/100g
Pharm ClassesAldosterone Antagonist [EPC],Aldosterone Antagonists [MoA],Retinoid [EPC],Retinoids [CS],Decreased Sebaceous Gland Activity [PE],Lincosamide Antibacterial [EPC],Lincosamides [CS]
NDC Exclude FlagN
Listing Certified Through2020-12-31

Packaging

NDC 72934-1052-2

30 g in 1 BOTTLE, PUMP (72934-1052-2)
Marketing Start Date2019-05-04
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 72934-1052-2 [72934105202]

CLINDAMYCIN 1% / NIACINAMIDE 4% / SPIRONOLACTONE 2% / TRETINOIN 0.025% GEL
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitGM
Marketing Start Date2019-05-04

Drug Details

Active Ingredients

IngredientStrength
SPIRONOLACTONE2 g/100g

Pharmacological Class

  • Aldosterone Antagonist [EPC]
  • Aldosterone Antagonists [MoA]
  • Retinoid [EPC]
  • Retinoids [CS]
  • Decreased Sebaceous Gland Activity [PE]
  • Lincosamide Antibacterial [EPC]
  • Lincosamides [CS]
  • Aldosterone Antagonist [EPC]
  • Aldosterone Antagonists [MoA]
  • Retinoid [EPC]
  • Retinoids [CS]
  • Decreased Sebaceous Gland Activity [PE]
  • Lincosamide Antibacterial [EPC]
  • Lincosamides [CS]

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.